It’s It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: Provention Bio hopes to get FDA approval of Teplizumab next month and partners with Sanofi on this T1D prevention drug, new type 2 studies show that younger people who develop it generally have worse health outcomes, Medicare considers expanded coverage of CGMs and more
Learn more about the T1D Exchange: www.T1Dexchange.org/Stacey
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners – they help make the show possible!
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
Provention Bio partners with Sanofi to help bring teplizumab to market. Teplizumab isn’t yet approved, the FDA is expected to give it the thumbs up later this year.. this is the drug shown to prevent type 1 diabetes for up to three years. Among other things, Sanofi will get exclusive global marketing rights for the drug. The FDA had asked for more information the last time teplizumab was up for approval.. the three month period for that closes in November.. and a ruling is expected then.
New research has found that the age at which people are diagnosed with type 2 diabetes is associated with a higher risk of developing serious complications.
The study, which was published in JAMA Network Open, analyzed health data from more than 36,000 Americans aged 50 and above.
The researchers found that those who were diagnosed with type 2 diabetes between the ages of 50 and 59 had “elevated risks” of heart disease, stroke, disability, cognitive impairment, and early death. But when people were diagnosed with diabetes later in life, the risks were reduced.1 No obvious reason for that.. but the researchers say it does point to the need for more screening and better prevention and treatment.
The Centers for Medicare and Medicaid Services has proposed new draft coverage guidelines for continuous glucose monitors.
Under the proposal, the CMS would cover CGMs for diabetes patients who are treated with insulin or “have a history of problematic hypoglycemia,” as defined by the frequency or severity of low blood sugar events, seemingly regardless of whether they have Type 1 or 2 diabetes.
Analysts at J.P. Morgan said the proposal reads “very favorably” for Abbott and Dexcom, leading CGM manufacturers that are targeting the “massive and highly under-penetrated Type 2 market opportunity.”
Mark cuban’s Cost Plus Drugs has joined with
to provide our patients with their line of Accu-ChekⓇ test strips, lancets, & meters!
This partnership will allow anyone to access what they need to check their blood sugar, at a low price.
Researchers who study Type 2 diabetes have reached a stark conclusion: There is no device, no drug powerful enough to counter the effects of poverty, pollution, stress, a broken food system, cities that are hard to navigate on foot and inequitable access to health care, particularly in minority communities. This is a long and complicated article published in the New York Times.. I’ll link it up and I urge you to read it. I can’t really to it justice in a short excerpt here.
“Our entire society is perfectly designed to create Type 2 diabetes,” said Dr. Dean Schillinger, a professor of medicine at University of California, San Francisco. “We have to disrupt that.”
Dr. Schillinger and nearly two dozen other experts laid out a road-map for doing so earlier this year in a comprehensive national report to Congress on diabetes, the first of its kind since 1975.
It calls for reframing the epidemic as a social, economic and environmental problem, and offers a series of detailed fixes, ranging from improving access to healthy food and clean water to rethinking the designs of communities, housing and transportation networks.
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
The Diabetes Design initiative is looking for college age people with type 1 to help them design the ultimate alarm for an extreme low. I’ll put the contact info in the show notes, along with a link to the website. By the way, I had never heard of the Diabetes Design Initiative but boy do I know these names and you probably do too. Ben West, Dana Lewis and a few others from the history of we are not waiting
Grace Zheng email@example.com
On the podcast next week.. teens and type 1 – a deep dive into why teen retreats work from the people who organize a great one.. and how adults with type 1 still use the lessons they learned as teens.
This past episode is all about Dexcom design.
Listen wherever you get your podcasts
Hey for you parents, we’ve got a webinar on Halloween, link in the show notes and on my social media.
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.